In Vitro Screening of Papillary and Reticular Fibroblast Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective agents to prevent and attenuate skin aging, particularly photo-aging, and to hydrate the skin, as they fail to specifically target key markers and mechanisms involved in skin aging and hydration.
Innovation Solution
An in vitro method for screening compounds that activates the expression of PDPN, CCRL1, and NTN1 genes in papillary fibroblasts and inhibits the expression of MGP, PPP1R14A, and TGM2 genes in reticular fibroblasts, using quantitative PCR to identify compounds that enhance skin hydration and anti-aging effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional screening methods are used to identify anti-aging compounds, then the screening process can be performed with existing techniques, but the ability to specifically target key markers and mechanisms involved in skin aging is insufficient
Solution Approach 1:
The patent segments the skin aging process into distinct molecular markers (PDPN, CCRL1, NTN1 for papillary fibroblasts; MGP, PPP1R14A, TGM2 for reticular fibroblasts) and develops separate detection strategies for each marker type, allowing precise targeting of specific aging mechanisms while maintaining manageable screening complexity
Solution Approach 2:
The patent utilizes quantitative PCR to measure gene expression levels as a key parameter, transforming the screening approach from qualitative to quantitative assessment. This enables precise measurement of marker expression changes in response to test compounds, significantly improving the specificity of identifying anti-aging compounds
2Reliability
If no specific markers are targeted in skin aging research, then the research approach is simpler, but effective agents to prevent and attenuate skin aging cannot be identified
Solution Approach 1:
The patent performs preliminary identification and validation of specific molecular markers (PDPN, CCRL1, NTN1, MGP, PPP1R14A, TGM2) that are differentially expressed in papillary and reticular fibroblasts during aging. This preliminary work establishes a reliable marker panel that can be used in subsequent screening assays, making the identification of effective anti-aging agents more reliable while managing the complexity of marker detection
Solution Approach 2:
The patent uses quantitative PCR as an intermediary tool to detect and measure the expression levels of specific gene markers. This intermediary technique bridges the gap between the complex biological markers and the screening process, enabling reliable detection and measurement of marker expression changes in response to test compounds
3Productivity
If compounds are screened without differentiating between papillary and reticular fibroblasts, then the screening process is simpler, but the ability to prevent cellular senescence and UV-induced cell senescence is reduced
Solution Approach 1:
The patent segments the fibroblast population into two distinct groups (papillary and reticular) based on their differential marker expression profiles. By developing separate screening approaches for each fibroblast type using their specific markers, the patent maintains screening efficiency while significantly improving the reliability of identifying compounds that can prevent cellular senescence and UV-induced damage
Solution Approach 2:
The patent applies local quality by tailoring the screening approach to each fibroblast subtype's specific characteristics. Papillary fibroblasts are screened using PDPN, CCRL1, and NTN1 markers, while reticular fibroblasts are screened using MGP, PPP1R14A, and TGM2 markers. This localized approach ensures that compounds identified are specifically effective for each fibroblast type, enhancing the overall reliability of anti-aging compound identification
Data Source
AI summary
An in vitro method for screening for candidate compounds for preventing and/or attenuating skin ageing, and/or hydrating skin, includes: a) contacting a test compound with a sample of papillary fibroblasts; b) measuring the expression of a gene selected from PDPN, CCRL1 and NTN1, in the papillary fibroblasts; and c) selecting compounds for which an activation of at least 1.5 fold of the expression of at least one of the genes is measured in the treated papillary fibroblasts compared with untreated papillary fibroblasts. Another in vitro method includes: a) contacting a test compound with a sample of reticular fibroblasts; b) measuring the expression of a gene selected from MGP, PPP1R14A and TGM2, in the reticular fibroblasts; and c) selecting compounds for which an activation of at most 1.0 fold of the expression of at least one of the genes is measured in the treated reticular fibroblasts compared with untreated reticular fibroblasts.